AstraZeneca and Daiichi sign $6.9bn cancer drug deal
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
Read More
Tag: HER2-targeting
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
